Acute lymphoblastic leukemia: Monitoring minimal residual disease as a therapeutic principle

Seminars in Oncology

Volumn 39, Issue 1, 2012, Pages 47-57

  Brüggemann, Monika ^a   Gökbuget, Nicola ^b   Kneba, Michael ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD45 ANTIGEN; COMPLEMENTARY DNA; ETHIDIUM BROMIDE; IMATINIB; IMMUNOGLOBULIN; MESSENGER RNA;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CHROMOSOME TRANSLOCATION; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INTERVENTION STUDY; LEUKEMIA CELL; LIMIT OF DETECTION; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MONITORING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STANDARDIZATION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84856390458     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.11.009     Document Type: Article

References (96)

1. N. Gökbuget, D. Hoelzer, R. Arnold Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL) Hematol Oncol Clin North Am 14 2000 1307 1325
2. D. Hoelzer, E. Thiel, H. Loffler Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults Blood 71 1988 123 131 (Pubitemid 18050401)
3. R.A. Larson, R.K. Dodge, C.P. Burns A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811 Blood 85 1995 2025 2037
4. J.M. Rowe, G. Buck, A.K. Burnett Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 Blood 106 2005 3760 3767 (Pubitemid 41739010)
5. A. Moricke, A. Reiter, M. Zimmermann Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood 111 2008 4477 4489
6. C.H. Pui, D. Campana, D. Pei Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 360 2009 2730 2741
7. D. Campana, C.H. Pui Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance Blood 85 1995 1416 1434
8. M. Brüggemann, V.H.J. van der Velden, T. Raff Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia Leukemia 18 2004 709 719 (Pubitemid 38528651)
9. D. Campana, E. Coustan-Smith Minimal residual disease studies by flow cytometry in acute leukemia Acta Haematol 112 2004 8 15 (Pubitemid 38716244)
10. H. Cave, C. Guidal, P. Rohrlich Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes Blood 83 1994 1892 1902 (Pubitemid 24107914)
11. E. Coustan-Smith, F.G. Behm, J. Sanchez Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 351 1998 550 554 (Pubitemid 28077560)
12. M.N. Dworzak, G. Froschl, D. Printz Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood 99 2002 1952 1958 (Pubitemid 34525474)
13. M.N. Dworzak, G. Gaipa, R. Ratei Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible Cytometry B Clin Cytom 74 2008 331 340
14. B. Gleissner, H. Rieder, E. Thiel Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data Leukemia 15 2001 1834 1840 (Pubitemid 33114988)
15. J. Irving, J. Jesson, P. Virgo Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting Haematologica 94 2009 870 874
16. G. Mitterbauer, P. Nemeth, S. Wacha Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction Br J Haematol 106 1999 634 643 (Pubitemid 29434200)
17. J. Radich, G. Gehly, A. Lee Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation Blood 89 1997 2602 2609 (Pubitemid 27143311)
18. V.H. Van der Velden, G. Cazzaniga, A. Schrauder Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data Leukemia 21 2007 604 611 (Pubitemid 46444541)
19. V.H.J. van der Velden, J.M. Wijkhuijs, D.C. Jacobs, E.R. van Wering, J.J.M. van Dongen T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis Leukemia 16 2002 1372 1380
20. V.H.J. van der Velden, M.J. Willemse, C.E. van der Schoot, K. Hahlen, E.R. van Wering, J.J.M. van Dongen Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR Leukemia 16 2002 928 936 (Pubitemid 34537567)
21. P. Bader, H. Kreyenberg, G.H.R. Henze Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group J Clin Oncol 27 2009 377 384
22. R. Bassan, O. Spinelli, E. Oldani Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood 113 2009 4153 4162
23. E. Bjorklund, J. Mazur, S. Soderhall, A. Porwit-MacDonald Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia Leukemia 17 2003 138 148 (Pubitemid 36175899)
24. M.J. Borowitz, M. Devidas, S.P. Hunger Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood 111 2008 5477 5485
25. M. Brüggemann, T. Raff, T. Flohr Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood 107 2006 1116 1123 (Pubitemid 43156313)
26. H. Cave, van der Werff ten Bosch, S. Suciu Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia European Organization for Research and Treatment of CancerChildhood Leukemia Cooperative Group N Engl J Med 339 1998 591 598
27. E. Coustan-Smith, J. Sancho, M.L. Hancock Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 96 2000 2691 2696
28. C. Eckert, A. Biondi, K. Seeger Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia Lancet 358 2001 1239 1241 (Pubitemid 33010852)
29. E. Fronkova, E. Mejstrikova, S. Avigad Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 22 2008 989 997 (Pubitemid 351689881)
30. N.J. Goulden, C.J. Knechtli, R.J. Garland Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia Br J Haematol 100 1998 235 244 (Pubitemid 28051867)
31. F. Huguet, T. Leguay, E. Raffoux Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study J Clin Oncol 27 2009 911 918
32. C.J. Knechtli, N.J. Goulden, J.P. Hancock Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood 92 1998 4072 4079 (Pubitemid 28544322)
33. C.J. Knechtli, N.J. Goulden, J.P. Hancock Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia Br J Haematol 102 1998 860 871 (Pubitemid 28387073)
34. S. Lee, D.W. Kim, B. Cho Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction Br J Haematol 120 2003 145 153 (Pubitemid 36056923)
35. S. Lee, D.W. Kim, Y.J. Kim Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 102 2003 3068 3070 (Pubitemid 37248885)
36. F.Y. Mortuza, M. Papaioannou, I.M. Moreira Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia J Clin Oncol 20 2002 1094 1104 (Pubitemid 34141855)
37. C. Nyvold, H.O. Madsen, L.P. Ryder Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome Blood 99 2002 1253 1258 (Pubitemid 34547078)
38. F. Pane, G. Cimino, B. Izzo Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia Leukemia 19 2005 628 635 (Pubitemid 40521168)
39. T. Raff, N. Gökbuget, S. Lschen Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials Blood 109 2007 910 915 (Pubitemid 46220634)
40. J.M. Ribera, A. Oriol, M. Gonzalez Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Final results of the CSTIBES02 trial Haematologica 95 2010 87 95
41. U.J. Scheuring, H. Pfeifer, B. Wassmann Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571) Blood 101 2003 85 90 (Pubitemid 36025891)
42. K. Schmiegelow, C. Nyvold, J. Seyfarth Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance Leukemia 15 2001 1066 1071 (Pubitemid 32717276)
43. J. Seyfarth, H.O. Madsen, C. Nyvold Post-induction residual disease in translocation t(12;21)-positive childhood ALL Med Pediatr Oncol 40 2003 82 87 (Pubitemid 35471370)
44. O. Spinelli, B. Peruta, M. Tosi Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia Haematologica 92 2007 612 618 (Pubitemid 350144263)
45. X. Thomas, J.M. Boiron, F. Huguet Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial J Clin Oncol 22 2004 4075 4086 (Pubitemid 41185176)
46. J.J. van Dongen, T. Seriu, E.R. Panzer-Grumayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738 (Pubitemid 28534955)
47. B. Wassmann, H. Pfeifer, N. Goekbuget Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 108 1998 1469 1477
48. V.H. Van der Velden, M. Bruggemann, P.G. Hoogeveen TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse Leukemia 18 2004 1971 1980 (Pubitemid 40028423)
49. V.H. Van der Velden, J.J. van Dongen MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR Methods Mol Biol 538 2009 115 150
50. G. Gaipa, G. Cazzaniga, R.E. Panzer-Grumayer Time point-dependent concordance of flow cytometry and RQ-PCR in the MRD detection in childhood ALL: the experience of the AIEOP-BFM- ALL MRD study group ASH Annual Meeting Abstracts 112 2008 700
51. M. Malec, V.H.J. van der Velden, E. Bjorklund Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping Leukemia 18 2004 1630 1636 (Pubitemid 39386341)
52. G.A. Neale, E. Coustan-Smith, P. Stow Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 18 2004 934 938 (Pubitemid 38714617)
53. E. Fronkova, K. Muzikova, E. Mejstrikova B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL Bone Marrow Transplant 42 2008 187 196
54. V.H.J. van der Velden, J.M. Wijkhuijs, J.J.M. van Dongen Non-specific amplification of patient-specific Ig//TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring Leukemia 22 2007 641 644 (Pubitemid 351386738)
55. D. Hoelzer, N. Gökbuget, O. Ottmann Acute lymphoblastic leukemia Hematology (Am Soc Hematol Educ Program) 2002 162 192
56. M. Zaliova, E. Fronkova, K. Krejcikova Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring Leukemia.l 23 2009 944 951
57. T. Burmeister, R. Marschalek, B. Schneider Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations Leukemia 20 2006 451 457 (Pubitemid 43291743)
58. C. Meyer, E. Kowarz, B. Schneider Genomic DNA of leukemic patients: target for clinical diagnosis of MLL rearrangements Biotechnol J 1 2006 656 663
59. V.H. Van der Velden, L. Corral, M.G. Valsecchi Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol Leukemia 23 2009 1073 1079
60. D. Campana, E. Coustan-Smith Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia Best Pract Res Clin Haematol 15 2002 1 19
61. M.N. Dworzak, G. Fritsch, C. Fleischer Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow Leukemia 11 1997 1266 1273 (Pubitemid 27387303)
62. M. Veltroni, L. De Zen, M.C. Sanzari Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia Haematologica 88 2003 1245 1252 (Pubitemid 37456379)
63. F. Weerkamp, E. Dekking, Y.Y. Ng Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients Leukemia 23 2009 1106 1107
64. D. Campana Determination of minimal residual disease in leukaemia patients Br J Haematol 121 2003 823 838 (Pubitemid 36760300)
65. E. Coustan-Smith, J. Sancho, F.G. Behm Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood 100 2002 52 58 (Pubitemid 35177428)
66. M.N. Dworzak, G. Froschl, D. Printz CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease Leukemia 18 2004 703 708 (Pubitemid 38500188)
67. E.R. van Wering, A. Beishuizen, E.T. Roeffen Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia Leukemia 9 1995 1523 1533
68. M.B. Vidriales, J.J. Perez, M.C. Lopez-Berges Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value Blood 101 2003 4695 4700 (Pubitemid 36857722)
69. M.N. Dworzak Immunological detection of minimal residual disease in acute lymphoblastic leukemia Onkologie 24 2001 442 448 (Pubitemid 33033406)
70. G. Kerst, H. Kreyenberg, C. Roth Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR Br J Haematol 128 2005 774 782 (Pubitemid 40444869)
71. N. Robillard, H. Cave, F. Mechinaud Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia Haematologica 90 2005 1516 1523 (Pubitemid 41658765)
72. M.N. Dworzak, A. Schumich, D. Printz CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy Blood 112 2008 3982 3988
73. G. Gaipa, G. Basso, O. Maglia Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection Leukemia 19 2005 49 56 (Pubitemid 40090076)
74. A.J. van der Sluijs-Gelling, V.H. Van der Velden, E.T. Roeffen, A.J. Veerman, E.R. van Wering Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death Leukemia 19 2005 1845 1847
75. E.R. van Wering, B.E. van der Linden-Schrever, T. Szczepanski Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease Br J Haematol 110 2000 139 146 (Pubitemid 30627499)
76. W.A. Stams, M.L. Den Boer, H.B. Beverloo Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia Haematologica 90 2005 1697 1699 (Pubitemid 41814997)
77. M.N. Dworzak, G. Gaipa, A. Schumich Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group Cytometry B Clin Cytom 78 2010 147 153
78. E.S. da Costa, R.T. Peres, J. Almeida Harmonization of light scatter and fluorescence flow cytometry profiles obtained after staining peripheral blood leucocytes for cell surface-only versus intracellular antigens with the Fix & Perm reagent Cytometry B Clin Cytom 78 2010 11 20
79. C.E. Pedreira, E.S. Costa, J. Almeida A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders Cytometry A 73A 2008 1141 1150
80. C.E. Pedreira, E.S. Costa, S. Barrena Generation of flow cytometry data files with a potentially infinite number of dimensions Cytometry A 73 2008 834 846
81. E.R. Panzer-Grumayer, M. Schneider, S. Panzer, K. Fasching, H. Gadner Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 95 2000 790 794 (Pubitemid 30062697)
82. B. Patel, L. Rai, G. Buck Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 Br J Haematol 148 2010 80 89
83. V. Conter, C.R. Bartram, M.G. Valsecchi Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 115 2010 3206 3214
84. D. Campana Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia Hematol Oncol Clin North Am 23 2009 1083 1098
85. P. Gameiro, F.Y. Mortuza, A.V. Hoffbrand, L. Foroni Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor g and d gene rearrangements Haematologica 87 2002 1126 1134 (Pubitemid 35397770)
86. M. Krampera, A. Vitale, C. Vincenzi Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia Br J Haematol 120 2003 74 79 (Pubitemid 36056911)
87. B. Wassmann, H. Pfeifer, M. Stadler Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 106 2005 458 463 (Pubitemid 40981238)
88. T. Leguay, F. Witz, S. De Botton Post-remission therapy with imatinib and HAM improve MRD before tansplant for patients with philadelphia-positive acute lymphoblastic leukemia (Ph+ALL): results of the GRAALL AFR03 Study ASH Annual Meeting Abstracts 108 2006 1877
89. O. Krejci, V.H. van der Velden, P. Bader Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD study group Bone Marrow Transplant 32 2003 849 851 (Pubitemid 38455954)
90. P. Bader, J. Hancock, H. Kreyenberg Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL Leukemia 16 2002 1668 1672
91. A.K. Fielding, S.M. Richards, R. Chopra Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Blood 109 2007 944 950 (Pubitemid 46220637)
92. T. Flohr, A. Schrauder, G. Cazzaniga Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia Leukemia 22 2008 771 782 (Pubitemid 351552626)
93. M. Brüggemann, A. Schrauder, T. Raff Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 Leukemia 24 2010 521 535
94. N. Gökbuget, R. Raff, M. Brüggemann Risk/MRD adapted GMALL trials in adult ALL Ann Hematol 83 Suppl 1 2004 S129 S131
95. N. Gökbuget, M. Kneba, T. Raff Risk-adapted treatment according to minimal residual disease in adult ALL Best Pract Res Clin Haematol 15 2002 639 652
96. J. Ribera, A. Oriol, M. Morgades Treatment of High-Risk (HR) Philadelphia chromosome-negative (Ph-) adult acute lymphoblastic leukemia (ALL) according to classical risk factors and minimal residual disease (MRD) Interim results of the PETHEMA ALL-AR-03 Trial ASH Annual Meeting Abstracts 108 2006 1872